# DESCRIPTION

## FIELD OF THE INVENTION

- relate to VAR2CSA fragments and antibodies

## BACKGROUND OF THE INVENTION

- introduce proteoglycans
- describe functions of proteoglycans
- describe malaria parasite life cycle
- describe VAR2CSA and its binding to CSA
- describe CSA structure and function
- describe CSPG4 and its expression
- describe early studies on IE sequestration
- describe structural requirements for CSA
- describe minimal inhibition of binding requirements

## OBJECT OF THE INVENTION

- provide minimal functional binding fragments of VAR2CSA

## SUMMARY OF THE INVENTION

- describe VAR2CSA binding to CSA
- suggest using VAR2CSA for targeting cancer cells

## a) ID1, and

- define minimal binding fragment of VAR2CSA

## c) ID2a.

- describe isolated protein fragment of VAR2CSA
- describe antibody that specifically binds VAR2CSA fragment
- describe nucleic acid molecules encoding VAR2CSA fragment
- describe vector comprising isolated nucleic acid molecule
- describe host cell comprising vector
- describe method for producing protein fragment
- describe conjugate or fusion protein comprising VAR2CSA polypeptide
- describe composition comprising protein fragment or conjugate
- describe protein fragment or conjugate for use as medicament or diagnostic agent
- describe method for detecting protein fragment or conjugate
- describe use of protein fragment or conjugate for treatment of indications
- describe method for treatment of indications
- describe method for preventing occurrence of indications
- describe use of protein fragment or conjugate as biomarker
- describe use of protein fragment or conjugate for immunization
- describe use of protein fragment or conjugate for targeting moiety
- describe method for isolation of cells expressing CD44 and/or CSPG4
- describe diagnostic method for detecting elevated CSA levels
- describe method for purification of CD44 and/or CSPG4

## DETAILED DISCLOSURE OF THE INVENTION

- introduce VAR2CSA protein
- describe VAR2CSA binding to CSA
- motivate VAR2CSA for cancer treatment
- describe VAR2CSA expression on cancer cells
- list cancer types with CSPG4 expression
- describe CSPG4 role in mitoses and metastases
- discuss CSPG4 presence on various cancer types
- describe VAR2CSA recombinant protein production
- discuss VAR2CSA binding specificity
- introduce smaller VAR2CSA recombinant parts
- describe VAR2CSA binding to CSA in various expression systems
- introduce single small antigen binding to CSA
- list VAR2CSA protein affinity to CSA
- describe VAR2CSA binding to various cancer cell lines
- introduce control molecule with truncated VAR2CSA
- describe VAR2CSA binding to CSPG4 expressing cell lines
- discuss advantages of targeting CSA with VAR2CSA
- describe VAR2CSA stability and polymorphism
- discuss VAR2CSA use in cancer treatment
- describe VAR2CSA use in other diseases and conditions
- introduce biotechnological tool uses for VAR2CSA
- list various uses of VAR2CSA polypeptides or conjugates
- describe VAR2CSA use in monitoring CSA levels
- discuss VAR2CSA use in treatment of arthritis and arthrosis

### DEFINITIONS

- define VAR2CSA polypeptide
- specify embodiments of VAR2CSA polypeptide
- define ID1
- define DBL2Xb
- define ID2a
- specify sequence identity
- define variant or variants
- specify functional activity of variants
- define functional variant, fragment, and derivatives
- specify binding affinity of functional variants
- define immunologic fragment
- define another amino acid
- define derivative
- define construct
- define vector
- define appropriate growth medium
- define treatment
- define subject
- define sequence identity
- define similarity
- explain conservative modifications
- explain conservative amino acid substitution
- define amino acid substitutions
- classify residues by side chain properties
- explain hydropathic index
- describe hydrophilicity values
- introduce epitopic core regions
- discuss conservative amino acid substitutions
- identify important residues for activity or structure
- analyze three-dimensional structure and sequence
- generate test variants with single amino acid substitutions
- predict secondary structure using homology modeling
- discuss threading, profile analysis, and evolutionary linkage
- calculate identity and similarity of related polypeptides
- describe computer program methods for determining identity and similarity
- explain the GCG program package, including GAP
- discuss the BLASTP, BLASTN, and FASTA programs
- describe the Smith Waterman algorithm
- explain the GAP program parameters
- discuss nucleic acid molecule sequence comparisons
- introduce the inventors' research questions
- express identical FCR3 and 3d7 VAR2CSA truncations
- demonstrate high CSA binding-affinity in shorter fragments
- define putative GAG binding sites in VAR2CSA
- show that mutations in GAG binding sites have no effect on CSPG binding
- discuss polyelectrolyte-protein interactions
- show that short VAR2CSA fragments induce adhesion-blocking antibodies
- target the proposed CSA binding region
- provide insight into the biochemical nature of VAR2CSA-CSA interaction
- discuss the importance of VAR2CSA sequence for CSA adhesion
- determine minimal structural requirements for VAR2CSA binding to CSA
- design an optimal vaccine antigen

### Preparation of VAR2CSA Polypeptides and Other Polypeptides of the Invention

- introduce VAR2CSA polypeptides
- describe recombinant nucleic acid techniques
- modify wild-type VAR2CSA nucleic acid sequence
- insert modified sequence into expression vector
- transform or transfect host cells
- use higher eukaryotic cells as host cells
- use procaryotic cells as host cells
- use yeast strains as host cells
- accomplish amino acid sequence alterations
- use site-specific mutagenesis
- use polymerase chain reaction
- incorporate non-naturally occurring amino acid residues
- use in vitro system with nonsense mutations
- use transcription and translation in cell-free system
- purify polypeptides by chromatography
- use microinjection of mutated mRNA
- culture E. coli cells in absence of natural amino acid
- convert naturally occurring amino acid residues
- prepare nucleic acid construct
- obtain genomic or cDNA library
- screen for DNA sequences by hybridization
- prepare nucleic acid construct synthetically
- use phosphoamidite method
- prepare mixed synthetic and genomic construct
- insert DNA sequences into recombinant vector
- use expression vector with promoter
- describe suitable promoters for mammalian cells
- describe suitable promoters for insect cells
- describe suitable promoters for yeast host cells
- introduce VAR2CSA polypeptides
- describe signal peptide
- describe ligation of DNA sequences
- describe transfecting mammalian cells
- describe expressing DNA sequences
- describe introducing selectable marker
- describe selecting stably transfected cells
- describe host cells for expression
- describe mammalian cell lines
- describe yeast cells
- describe fungal cells
- describe transforming filamentous fungi
- describe transforming insect cells
- describe culturing host cells
- describe recovering Plasmodium falciparum VAR2CSA polypeptide
- describe transgenic animal technology
- describe producing VAR2CSA polypeptides in mammary glands
- describe selecting host species
- describe using milk protein gene promoter
- describe using beta lactoglobulin promoter
- describe incorporating genomic regions
- describe using introns
- describe replacing VAR2CSA pre pro and 5' non coding sequences
- describe constructing expression units
- describe introducing expression units into fertilized eggs
- describe producing transgenic animals
- describe general procedures for producing transgenic animals
- describe introducing foreign DNA sequences into mammals
- describe adapting techniques for larger animals
- describe injecting DNA into fertilized eggs
- describe production in transgenic plants
- describe generalized expression
- describe directed expression to particular organs
- describe examples of transgenic plants

### VAR2CSA Purification

- introduce purification methods
- describe affinity chromatography
- define isolated polypeptide
- define microorganism

### Combination Treatments

- define combination treatments
- introduce VAR2CSA polypeptide
- describe simultaneous dosing
- describe sequential dosing
- introduce other cancer agents
- list specific cancer agents
- introduce pharmaceutical formulation
- define aqueous formulation
- define aqueous solution
- define aqueous suspension
- introduce freeze-dried formulation
- introduce dried formulation
- specify pH range
- list specific pH values
- introduce buffer system
- list specific buffers
- introduce preservative
- list specific preservatives
- specify preservative concentration
- introduce isotonic agent
- list specific isotonic agents
- specify isotonic agent concentration
- introduce chelating agent
- list specific chelating agents
- specify chelating agent concentration
- introduce stabilizer
- list specific stabilizers
- introduce amino acid base
- list specific amino acids
- introduce methionine analogue
- specify methionine oxidation inhibition
- define combination treatments
- list surfactants
- motivate surfactant use
- describe additional ingredients
- outline administration routes
- describe dosage forms
- motivate drug carriers
- list drug carriers
- describe pulmonary administration
- motivate controlled release systems
- list controlled release systems
- describe production methods
- motivate parenteral administration
- describe parenteral administration methods
- motivate transdermal administration
- define stabilized formulation
- define physical stability
- describe physical stability evaluation
- define chemical stability
- describe chemical stability evaluation
- motivate stability during use and storage
- describe stability requirements
- describe stability embodiments
- describe further stability embodiments
- describe even further stability embodiments
- describe additional stability embodiments
- summarize combination treatments
- summarize surfactant use
- summarize administration routes
- summarize dosage forms
- summarize drug carriers
- summarize controlled release systems

### Indications for Use of VAR2CSA Polypeptide and Conjugates Thereof

- list cancer indications
- identify micro-metastasis
- target cartilage and neural tissue
- target CSPG production

### Therapeutic or Diagnostic Effector Moiety, Such as Cytotoxic and Detecting Moieties

- introduce therapeutic effector moiety
- define VAR2CSA polypeptide sequence
- add protease inhibitor
- add toxin protein sequence
- describe cytotoxic moieties
- list chemotherapeutics
- describe conjugates of albumin
- introduce therapeutic enzymes
- describe killing of cells
- define therapeutic effector moiety
- list anticancer agents
- describe cell-penetrating peptides

### Radionuclides

- introduce radionuclides for medical imaging
- list radionuclides for medical imaging
- introduce radionuclides for therapy
- list radionuclides for therapy
- describe radiolabeling with chelators
- describe radiolabeling with indirect labeling
- introduce linker molecules
- describe linker molecule reactions
- list fluorophores and fluorochromes
- describe use of fluorophores and fluorochromes
- introduce conjugates with detecting moieties
- describe use of conjugates with detecting moieties
- introduce steroid hormones or anti-inflammatory agents
- describe conjugation with anti-inflammatory agents
- list anti-inflammatory agents
- introduce CSPG4
- describe conjugation with CSPG4
- describe use of CSPG4 conjugates
- introduce targeting of CD44 or other proteoglycans
- describe targeting of CD44 expressing cells
- describe targeting of CSPG4 negative cells
- introduce use in isolation of cancer stem cells
- describe use in isolation of cancer stem cells
- introduce use in isolation or detection of CTCs
- describe use in isolation or detection of CTCs
- introduce anti-idiotypic antibodies
- describe preparation of anti-idiotypic antibodies
- describe use of anti-idiotypic antibodies
- introduce specific embodiments of the invention
- describe isolated protein fragment of VAR2CSA
- describe binding affinity of protein fragment
- describe sequence identity of protein fragment
- describe length of protein fragment
- describe purity of protein fragment
- describe use of protein fragment in treatment of cancer

## EXAMPLES

### Production of Truncated Recombinant VAR2CSA Proteins

- produce truncated VAR2CSA proteins
- characterize protein structure

### VAR2CSA from FCR3 and 3D7 Binds CSA with Similar Affinity and Specificity

- produce VAR2CSA fragments from FCR3 and 3D7
- screen for CSPG binding
- analyze binding kinetics

### The Core-CSA Binding Site Lies within the DBL2X Domain

- analyze truncated VAR2CSA fragments for CSA binding
- identify minimal CSA binding region

### Antibodies Induced Against Novel Minimum Binding Regions Induce a Potent Parasite Anti-Adhesive Immune Response

- immunize rats with VAR2CSA fragments
- test antibody inhibition of IE adhesion

### Example 5

- examine inhibitory anti-FV2 response
- affinity purify FV2 antibodies
- test inhibitory capacity of antibodies
- indicate epitopes inducing anti-adhesive antibodies
- mutate putative GAG binding sites
- characterize CSA-binding site
- test effect of mutations on CSPG binding
- substitute basic amino acids with alanines
- delete DSM region
- test effect of deletion on CSPG binding
- indicate VAR2CSA-CSA binding mechanism
- test ionic dependence of VAR2CSA-CSA binding
- describe polyelectrolyte theory
- test binding of VAR2CSA to CSPG at different NaCl concentrations
- determine KD values
- estimate ionic interactions involved in binding
- indicate high CSA affinity for VAR2CSA
- test binding of VAR2CSA to cancer cells
- use flow-cytometry to analyze binding
- test binding of ID1-ID2a to various cancer cell lines
- use ID1-DBL2Xa as negative control
- test binding of VAR2CSA to CHO cells
- inhibit VAR2CSA binding to cells with CSA
- analyze binding affinity of VAR2CSA to cancer cells
- use Quartz Crystal Microbalance biosensor
- test binding of VAR2CSA to primary cancer tissue
- use immunohistochemistry to analyze binding
- Analyze intracellular signaling events
- Investigate Rac1 activity
- Measure reactive oxygen species
- Detect immunoblotting of pathway components
- Analyze signaling pathways affected by VAR2CSA
- Perform unbiased analysis of intracellular signaling events
- Analyze expression microarray technology
- Investigate inhibitory effect on ERK signaling
- Inhibit cancer cell growth in vivo
- Address five main questions in vivo
- Track micro-metastasis in vivo
- Internalize recombinant VAR2CSA proteins
- Analyze internalization of VAR2CSA
- Fuse VAR2CSA-toxin protein
- Analyze cytotoxic activity
- Analyze anti-tumor effect of cytotoxic compounds
- Couple cytotoxic compounds to VAR2CSA
- Analyze delivery and retention of VAR2CSA:compound-fusions
- Purify CSA-expressing stem cells
- Analyze expression of stem cell markers
- Identify and target CD44-expressing cancer stem cells
- Detect circulating tumor cells
- Identify potential CSPG molecules targeted by VAR2CSA
- Verify interaction between VAR2CSA and receptors

## DISCUSSION

- introduce malaria as a global health problem
- motivate VAR2CSA-CSA interaction study
- summarize previous work on VAR2CSA-CSA interaction
- describe truncations of VAR2CSA
- identify core CSA-binding site in DBL2X
- discuss limitations of single DBL domain binding
- highlight importance of ID1 and ID2a interdomains
- describe immunogenic characteristics of VAR2CSA fragments
- test anti-VAR2CSA sera in homologous inhibition
- discuss interclonal diversity among parasite variants
- predict GAG binding site structure
- mutate putative GAG binding sites
- examine ionic interactions in VAR2CSA-CSA binding
- discuss nonionic interactions in VAR2CSA-CSA binding
- hypothesize multivalent interaction mechanism
- summarize potential of VAR2CSA fragment as vaccine candidate

### Methods

- clone VAR2CSA sequence fragments
- amplify fragments using PCR
- express proteins in insect cells
- purify proteins using dialysis and chromatography
- verify protein purity using SDS-PAGE
- perform ELISA
- coat microtiter plates with CSPG or HSPG
- block plates with TSM binding buffer
- add protein to plates and incubate
- wash plates and add anti-V5-HRP antibody
- develop plates with o-phenylenediamine substrate
- perform Quartz Crystal Microbalance measurements
- coat quartz crystal with CSPG or HSPG
- block plate with PBS containing Ig-free BSA
- inject analyte and measure association and dissociation
- perform Salt Titration Assay
- coat plates with CSPG
- add protein to plates and incubate
- calculate KD values using non-linear regression
- immunize animals with recombinant protein
- extract serum from immunized animals
- affinity purify IgG using NHS-activated HP column
- maintain P. falciparum parasite cultures
- purify late-stage trophozoites using MACS CS-column
- measure antibody binding to native VAR2CSA using flow cytometry
- inhibit parasite binding to CSPG using serum antibodies

